

# Heinz Laubli

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6659307/publications.pdf>

Version: 2024-02-01

68  
papers

5,003  
citations

186265

28  
h-index

123424

61  
g-index

77  
all docs

77  
docs citations

77  
times ranked

7367  
citing authors

#	ARTICLE	IF	CITATIONS
1	Targeting immunoliposomes to EGFR-positive glioblastoma. <i>ESMO Open</i> , 2022, 7, 100365.	4.5	42
2	Siglec Receptors Modulate Dendritic Cell Activation and Antigen Presentation to T Cells in Cancer. <i>Frontiers in Cell and Developmental Biology</i> , 2022, 10, 828916.	3.7	16
3	Glycosaminoglycans in cancer therapy. <i>American Journal of Physiology - Cell Physiology</i> , 2022, 322, C1187-C1200.	4.6	12
4	Larotrectinib Response in NTRK3 Fusion-Driven Diffuse High-Grade Glioma. <i>Pharmacology</i> , 2022, 107, 433-438.	2.2	9
5	Effects of COVID-19 Lockdown on Melanoma Diagnosis in Switzerland: Increased Tumor Thickness in Elderly Females and Shift towards Stage IV Melanoma during Lockdown. <i>Cancers</i> , 2022, 14, 2360.	3.7	10
6	A phase I/II study of ANV419, a selective IL-2R-beta-gamma targeted antibody-IL-2 fusion protein, in patients with advanced solid tumors.. <i>Journal of Clinical Oncology</i> , 2022, 40, e21552-e21552.	1.6	2
7	NK cells with tissue-resident traits shape response to immunotherapy by inducing adaptive antitumor immunity. <i>Science Translational Medicine</i> , 2022, 14, .	12.4	29
8	Tools to study and target the Siglec-sialic acid axis in cancer. <i>FEBS Journal</i> , 2021, 288, 6206-6225.	4.7	27
9	Mechanisms of Immune-Related Complications in Cancer Patients Treated with Immune Checkpoint Inhibitors. <i>Pharmacology</i> , 2021, 106, 123-136.	2.2	24
10	Targeting glyco-immune checkpoints for cancer therapy. <i>Expert Opinion on Biological Therapy</i> , 2021, 21, 1063-1071.	3.1	12
11	Cross-Reactivity and Functionality of Approved Human Immune Checkpoint Blockers in Dogs. <i>Cancers</i> , 2021, 13, 785.	3.7	15
12	Multidisciplinary tumor boards as videoconferences – a new challenge in the COVID-19 era. <i>Annals of Oncology</i> , 2021, 32, 572-573.	1.2	7
13	Fitness-to-drive for glioblastoma patients. <i>Swiss Medical Weekly</i> , 2021, 151, w20501.	1.6	3
14	A Standardized Analysis of Tertiary Lymphoid Structures in Human Melanoma: Disease Progression- and Tumor Site-Associated Changes With Germinal Center Alteration. <i>Frontiers in Immunology</i> , 2021, 12, 675146.	4.8	31
15	Loss of Lymphotoxin Alpha-Expressing Memory B Cells Correlates with Metastasis of Human Primary Melanoma. <i>Diagnostics</i> , 2021, 11, 1238.	2.6	6
16	EXTH-45. MICROGLIA-SPECIFIC DISRUPTION OF SIALIC ACID-SIGLEC-9/E INTERACTIONS: A NOVEL IMMUNOTHERAPY AGAINST GLIOBLASTOMA?. <i>Neuro-Oncology</i> , 2021, 23, vi173-vi173.	1.2	0
17	Sialic acid-binding immunoglobulin-like lectins (Siglecs) detect self-associated molecular patterns to regulate immune responses. <i>Cellular and Molecular Life Sciences</i> , 2020, 77, 593-605.	5.4	118
18	Tumor mutational burden assessed by targeted NGS predicts clinical benefit from immune checkpoint inhibitors in non-small cell lung cancer. <i>Journal of Pathology</i> , 2020, 250, 19-29.	4.5	92

#	ARTICLE	IF	CITATIONS
19	Tumor-associated carbohydrates and immunomodulatory lectins as targets for cancer immunotherapy. , 2020, 8, e001222.		60
20	Hyperglycemia Enhances Cancer Immune Evasion by Inducing Alternative Macrophage Polarization through Increased O-GlcNAcylation. Cancer Immunology Research, 2020, 8, 1262-1272.	3.4	32
21	716P Optimizing ipilimumab in metastatic renal cell carcinoma: SAKK 07/17 study. Annals of Oncology, 2020, 31, S563.	1.2	2
22	Targeted glycan degradation potentiates the anticancer immune response in vivo. Nature Chemical Biology, 2020, 16, 1376-1384.	8.0	192
23	A Sweet Approach to Heat Up Cancer Response to Immunotherapy. Cancer Discovery, 2020, 10, 1789-1790.	9.4	2
24	Response to Comment on Trinh et al. Successful Treatment of Immune Checkpoint Inhibitor-Induced Diabetes With Infliximab. Diabetes Care 2019;42:e153â€“e154. Diabetes Care, 2020, 43, e11-e11.	8.6	2
25	Fibroblast activation protein-targeted-4-1BB ligand agonist amplifies effector functions of intratumoral T cells in human cancer. , 2020, 8, e000238.		35
26	PD-1+ natural killer cells in human non-small cell lung cancer can be activated by PD-1/PD-L1 blockade. Cancer Immunology, Immunotherapy, 2020, 69, 1505-1517.	4.2	58
27	A contemporary perspective on the diagnosis and treatment of diffuse gliomas in adults. Swiss Medical Weekly, 2020, 150, w20256.	1.6	5
28	Immune tumor board: integral part in the multidisciplinary management of cancer patients treated with cancer immunotherapy. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2019, 474, 485-495.	2.8	3
29	Altered Cell Adhesion and Glycosylation Promote Cancer Immune Suppression and Metastasis. Frontiers in Immunology, 2019, 10, 2120.	4.8	153
30	B cells sustain inflammation and predict response to immune checkpoint blockade in human melanoma. Nature Communications, 2019, 10, 4186.	12.8	236
31	Therapeutic Targeting of Golgi Phosphoprotein 2 (GOLPH2) with Armed Antibodies: A Preclinical Study of Anti-GOLPH2 Antibody Drug Conjugates in Lung and Colorectal Cancer Models of Patient Derived Xenografts (PDX). Targeted Oncology, 2019, 14, 577-590.	3.6	4
32	The sialoglycan-Siglec glyco-immune checkpoint â€“ a target for improving innate and adaptive anti-cancer immunity. Expert Opinion on Therapeutic Targets, 2019, 23, 839-853.	3.4	72
33	GEF-H1 Signaling upon Microtubule Destabilization Is Required for Dendritic Cell Activation and Specific Anti-tumor Responses. Cell Reports, 2019, 28, 3367-3380.e8.	6.4	37
34	Uncoupling protein 2 reprograms the tumor microenvironment to support the anti-tumor immune cycle. Nature Immunology, 2019, 20, 206-217.	14.5	51
35	Association of Checkpoint Inhibitor-Induced Toxic Effects With Shared Cancer and Tissue Antigens in Non-â€“Small Cell Lung Cancer. JAMA Oncology, 2019, 5, 1043.	7.1	266
36	Siglec-9 Regulates an Effector Memory CD8+ T-cell Subset That Congregates in the Melanoma Tumor Microenvironment. Cancer Immunology Research, 2019, 7, 707-718.	3.4	94

#	ARTICLE	IF	CITATIONS
37	Inflammation-induced hypoparathyroidism triggered by combination immune checkpoint blockade for melanoma. , 2019, 7, 52.		43
38	A Variant of a Killer Cell Immunoglobulin-like Receptor Is Associated with Resistance to PD-1 Blockade in Lung Cancer. Clinical Cancer Research, 2019, 25, 3026-3034.	7.0	29
39	Successful Treatment of Immune Checkpoint Inhibitorâ€“Induced Diabetes With Infliximab. Diabetes Care, 2019, 42, e153-e154.	8.6	29
40	Toxicity associated with PD-1 blockade after allogeneic haematopoietic cell transplantation. Swiss Medical Weekly, 2019, 149, w20150.	1.6	3
41	Targeting sialic acidâ€“Siglec interactions to reverse immune suppression in cancer. Glycobiology, 2018, 28, 640-647.	2.5	115
42	The multi-receptor inhibitor axitinib reverses tumor-induced immunosuppression and potentiates treatment with immune-modulatory antibodies in preclinical murine models. Cancer Immunology, Immunotherapy, 2018, 67, 815-824.	4.2	42
43	The T cell repertoire in tumors overlaps with pulmonary inflammatory lesions in patients treated with checkpoint inhibitors. Oncoimmunology, 2018, 7, e1386362.	4.6	62
44	Treatment of mycophenolate-resistant immune-related organizing pneumonia with infliximab. , 2018, 6, 85.		19
45	Influenza vaccination of cancer patients during PD-1 blockade induces serological protection but may raise the risk for immune-related adverse events. , 2018, 6, 40.		110
46	Cancer Immunotherapy. Glycobiology, 2018, 28, 638-639.	2.5	5
47	Self-associated molecular patterns mediate cancer immune evasion by engaging Siglecs on T cells. Journal of Clinical Investigation, 2018, 128, 4912-4923.	8.2	214
48	Immunotherapy in head and neck cancer â€“ scientific rationale, current treatment options and future directions. Swiss Medical Weekly, 2018, 148, w14625.	1.6	23
49	Cerebral vasculitis mimicking intracranial metastatic progression of lung cancer during PD-1 blockade. , 2017, 5, 46.		64
50	Cell Adhesion During Tumorigenesis and Metastasis. , 2017, , .		2
51	The immune system and cancer evasion strategies: therapeutic concepts. Journal of Internal Medicine, 2016, 279, 541-562.	6.0	212
52	Antimetastatic Properties of Low Molecular Weight Heparin. Journal of Clinical Oncology, 2016, 34, 2560-2561.	1.6	10
53	Sialic acids in cancer biology and immunity. Glycobiology, 2016, 26, 111-128.	2.5	364
54	Lenalidomide monotherapy leads to a complete remission in refractory B-cell post-transplant lymphoproliferative disorder. Leukemia and Lymphoma, 2016, 57, 945-948.	1.3	5

#	ARTICLE	IF	CITATIONS
55	A red meat-derived glycan promotes inflammation and cancer progression. Proceedings of the National Academy of Sciences of the United States of America, 2015, 112, 542-547.	7.1	327
56	Reply to Mackenzie: A comparison of Neu5Gc and $\alpha$ -gal xenoantigens. Proceedings of the National Academy of Sciences of the United States of America, 2015, 112, E1405.	7.1	2
57	Acute heart failure due to autoimmune myocarditis under pembrolizumab treatment for metastatic melanoma. , 2015, 3, 11.		274
58	Siglec receptors impact mammalian lifespan by modulating oxidative stress. ELife, 2015, 4, .	6.0	56
59	Hormesis in cancer immunology. OncoImmunology, 2014, 3, e29312.	4.6	16
60	Lectin Galactoside-binding Soluble 3 Binding Protein (LGALS3BP) Is a Tumor-associated Immunomodulatory Ligand for CD33-related Siglecs. Journal of Biological Chemistry, 2014, 289, 33481-33491.	3.4	87
61	Involvement of a Non-Human Sialic Acid in Human Cancer. Frontiers in Oncology, 2014, 4, 33.	2.8	126
62	Engagement of myelomonocytic Siglecs by tumor-associated ligands modulates the innate immune response to cancer. Proceedings of the National Academy of Sciences of the United States of America, 2014, 111, 14211-14216.	7.1	186
63	Inverse hormesis of cancer growth mediated by narrow ranges of tumor-directed antibodies. Proceedings of the National Academy of Sciences of the United States of America, 2014, 111, 5998-6003.	7.1	64
64	Selectins as Mediators of Lung Metastasis. Cancer Microenvironment, 2010, 3, 97-105.	3.1	70
65	Selectins promote tumor metastasis. Seminars in Cancer Biology, 2010, 20, 169-177.	9.6	381
66	Heparins Attenuate Cancer Metastasis: Are Selectins the Link?. Cancer Investigation, 2009, 27, 474-481.	1.3	23
67	Selectin-mediated activation of endothelial cells induces expression of CCL5 and promotes metastasis through recruitment of monocytes. Blood, 2009, 114, 4583-4591.	1.4	127
68	L-Selectin Facilitation of Metastasis Involves Temporal Induction of Fut7-Dependent Ligands at Sites of Tumor Cell Arrest. Cancer Research, 2006, 66, 1536-1542.	0.9	140